Efficacy of Felbamate in the Treatment of Intractable Pediatric Epilepsy

Zupanc, Mary L.; Werner, Rhonda Roell; Schwabe, Michael; O'Connor, Sunila E.; Marcuccilli, Charles J.; Hecox, Kurt; Chico, Maria S.; Eggener, Kathy A.

doi:10.1016/j.pediatrneurol.2010.02.013

Cited by 38 publications

(35 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zupanc et al. [27] observed that seizure frequency was significantly reduced in the majority of 38 pediatric patients studied; 17% were completely seizure‐free. Anecdotal reports also showed a dramatic clinical response to felbamate by a child with acquired epileptic aphasia [28] and underlined the effectiveness of the drug in another child with West syndrome [29].…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review

Grosso

Cordelli

Coppola

et al. 2008

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review

Grosso

Cordelli

Coppola

et al. 2008

Euro J of Neurology

View full text Add to dashboard Cite

show abstract

“…1 In a pediatric specific study doses were titrated to a maintenance dose of 30 mg/kg daily, although some patients required and tolerated doses up to 100 mg/kg daily without experiencing adverse effects. 3 Although symptoms associated with FBM overdose appear to be mild, there are reports of mixed felbamate-valproate overdose associated with crystalluria and acute renal failure, and of crystalluria associated with FBM overdose alone. 5Ϫ7 In a child with FBM overdose microscopic examination of the crystals demonstrated they were needle shaped and measured 90 to 1,300 m. 6 The authors noted that their appearance suggested physical trauma to the renal tubular cells as a possible etiology for stones in these patients.…”

Section: Discussionmentioning

confidence: 99%

“…Given the refractory nature of the seizures, these cases may require high doses of felbamate for seizure management. 3 To our knowledge only 1 case report of felbamate urolithiasis exists in the literature. 4 In that instance a 15-year-old male presented with recurrent urinary stones.…”

mentioning

confidence: 96%

Urolithiasis in Patients on High Dose Felbamate

Ghousheh

Groth

Fryjoff³

et al. 2013

Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Felbamate was first approved by the US FDA in 1993 but reports of aplastic anaemia and hepatic failure emerged and led to a marked reduction in its use. However, it has been demonstrated to be effective in a recent study of children with LGS [123]. Potassium bromide is the oldest known anti-epileptic drug and has recently re-emerged as a useful adjunctive treatment for severe early-onset epileptic encephalopathies [123].…”

Section: Anti-epileptic Medications (Aeds)mentioning

confidence: 99%

Epileptic Encephalopathies: New Genes and New Pathways

Nieh

Sherr

2014

Neurotherapeutics

View full text Add to dashboard Cite

Epileptic encephalopathies represent a group of devastating epileptic disorders that occur early in life and are often characterized by pharmaco-resistant epilepsy, persistent severe electroencephalographic abnormalities, and cognitive dysfunction or decline. Next generation sequencing technologies have increased the speed of gene discovery tremendously. Whereas ion channel genes were long considered to be the only significant group of genes implicated in the genetic epilepsies, a growing number of non-ion-channel genes are now being identified. As a subgroup of the genetically mediated epilepsies, epileptic encephalopathies are complex and heterogeneous disorders, making diagnosis and treatment decisions difficult. Recent exome sequencing data suggest that mutations causing epileptic encephalopathies are often sporadic, typically resulting from de novo dominant mutations in a single autosomal gene, although inherited autosomal recessive and X-linked forms also exist.In this review we provide a summary of the key features of several early-and mid-childhood onset epileptic encephalopathies including Ohtahara syndrome, Dravet syndrome, Infantile spasms and Lennox Gastaut syndrome. We review the recent next generation sequencing findings that may impact treatment choices. We also describe the use of conventional and newer anti-epileptic and hormonal medications in the various syndromes based on their genetic profile. At a biological level, developments in cellular reprogramming and genome editing represent a new direction in modeling these pediatric epilepsies and could be used in the development of novel and repurposed therapies.

show abstract

Efficacy of Felbamate in the Treatment of Intractable Pediatric Epilepsy

Cited by 38 publications

References 15 publications

Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review

Efficacy and safety of felbamate in children under 4 years of age: a retrospective chart review

Urolithiasis in Patients on High Dose Felbamate

Epileptic Encephalopathies: New Genes and New Pathways

Contact Info

Product

Resources

About